Chronic Respiratory Disease (CRD - Mycoplasma)

Chronic respiratory disease stands as one of the most economically significant and widespread respiratory conditions affecting commercial poultry worldwide. Caused primarily by Mycoplasma gallisepticum, this persistent bacterial infection affects the respiratory tract of chickens and turkeys, causing clinical disease that ranges from mild respiratory signs to severe illness when complicated by secondary pathogens. The chronic nature of the infection means that once established in a flock, the organism persists indefinitely unless aggressive intervention including depopulation occurs. Understanding this disease is fundamental for poultry producers seeking to maintain flock health and productivity.

The disease affects chickens and turkeys as the primary hosts, though other poultry species including game birds can also become infected. Commercial layers, breeders, and broilers all demonstrate susceptibility, though the economic impact varies by production type. The condition is found globally wherever poultry are raised, with prevalence varying based on regional management practices, biosecurity standards, and the availability of mycoplasma-free breeding stock. Backyard flocks frequently harbor infection that can spread to commercial operations through various transmission routes.

The economic and welfare impact of chronic respiratory disease extends across multiple production parameters. Infected broiler flocks show reduced growth rates, increased feed conversion ratios, and elevated condemnation rates at processing. Layer flocks experience significant egg production drops, often ten to twenty percent below normal levels during acute disease phases. Eggshell quality deterioration and increased embryonic mortality in breeding flocks compound losses. From a welfare perspective, affected birds experience respiratory distress, reduced comfort, and diminished quality of life that persists throughout the chronic infection course.

Early detection and proper management significantly influence outcomes in flocks affected by chronic respiratory disease. While the infection cannot be truly cured, timely intervention limits production impacts and prevents progression to severe complicated disease. Veterinary involvement is essential for accurate diagnosis, treatment planning, and implementation of control programs. Understanding the chronic nature of mycoplasma infection helps producers set realistic expectations and develop long-term management strategies rather than seeking impossible complete elimination from positive flocks.

Chronic respiratory disease is caused by Mycoplasma gallisepticum, a unique bacterial organism that lacks a cell wall and represents the smallest self-replicating bacterium known to infect poultry. The absence of a cell wall makes mycoplasmas inherently resistant to certain antibiotics that target cell wall synthesis, including penicillins and cephalosporins. Mycoplasma gallisepticum attaches to respiratory epithelial cells, damaging the mucociliary clearance system and creating conditions favorable for secondary bacterial invasion. A related organism, Mycoplasma synoviae, often co-infects with M. gallisepticum and contributes to the chronic respiratory disease complex.

Genetic and breed susceptibility to chronic respiratory disease varies among poultry populations. Some genetic lines demonstrate relative resistance to mycoplasma colonization and clinical disease development, though no lines are completely immune. Fast-growing broiler genetics may experience more severe production impacts than slower-growing alternatives. Heritage breeds often show greater natural resistance than intensively selected commercial lines. Breeding companies have incorporated mycoplasma resistance into selection programs, though maintaining mycoplasma-free status remains the primary approach to protecting commercial breeding stock.

Environmental and management factors profoundly influence chronic respiratory disease severity and transmission dynamics. Poor ventilation leading to elevated ammonia levels damages respiratory epithelia and enhances mycoplasma pathogenicity. Overcrowding increases transmission opportunities and stress-related immunosuppression. Dust accumulation harbors organisms and creates respiratory irritation. Temperature extremes, particularly cold stress, increase susceptibility and disease severity. Multi-age operations allow continuous transmission from older carrier birds to susceptible young stock.

Risk factors for chronic respiratory disease development encompass both exposure and susceptibility considerations. Vertical transmission from infected breeder hens to their offspring represents a primary introduction route. Horizontal transmission occurs through aerosol exposure, contaminated equipment, and personnel moving between infected and susceptible flocks. Concurrent viral infections, particularly infectious bronchitis and Newcastle disease, dramatically increase disease severity. Immunosuppression from any cause, including infectious bursal disease exposure, heightens susceptibility and clinical impact.

The pathophysiology of chronic respiratory disease involves progressive colonization and damage to respiratory tissues. Mycoplasma organisms attach to epithelial cells lining the respiratory tract, interfering with normal ciliary function and mucus clearance. The resulting tissue damage attracts inflammatory cells and creates exudate accumulation. Secondary bacterial invasion, particularly by Escherichia coli, transforms relatively mild mycoplasma infection into severe complicated disease affecting air sacs and deeper tissues. The chronic carrier state develops as surviving organisms persist in respiratory tissues despite host immune responses, enabling lifelong infection and periodic shedding.

Early warning signs of chronic respiratory disease often appear subtle and require careful observation to detect. Slightly increased respiratory sounds may be heard during quiet periods, particularly at night when birds are resting. Mild snicking or sneezing sounds represent early indicators that experienced personnel learn to recognize. Feed consumption may decline slightly before obvious clinical signs develop. Egg production in laying flocks may begin declining before respiratory signs become apparent. These early signs offer opportunities for intervention before disease progression.

Common symptoms of chronic respiratory disease vary somewhat between chickens and turkeys but share core characteristics. Chickens typically display nasal discharge ranging from clear to thick and mucoid, with progression to purulent discharge in complicated cases. Foamy eyes and periorbital swelling develop as infraorbital sinuses become involved. Rales and respiratory sounds become progressively more audible as disease advances. Turkeys often show more pronounced infraorbital sinus swelling creating a characteristic swollen face appearance. Air sac involvement produces additional respiratory compromise.

Behavioral changes accompany chronic respiratory disease progression and provide diagnostic clues. Affected birds become less active and spend increased time resting. Reduced feed and water consumption leads to weight loss or failure to achieve expected growth. Birds may shake their heads attempting to clear nasal passages. Decreased social interaction and reduced vocalization occur as birds feel increasingly unwell. In laying flocks, birds may show reluctance to enter nest boxes, contributing to floor egg problems. Huddling behavior even at appropriate temperatures suggests illness.

Physical signs of chronic respiratory disease become increasingly obvious as infection advances. Nasal discharge accumulates around nares and may mat facial feathers. Periorbital swelling distorts normal facial appearance. Swollen infraorbital sinuses create characteristic facial bulging particularly noticeable in turkeys. Respiratory sounds including rales, coughing, and sneezing become audible from distances. Conjunctivitis causes eye irritation and tearing. In advanced complicated cases, body condition deteriorates with muscle wasting evident.

Symptom progression in chronic respiratory disease typically follows a predictable course influenced by complicating factors. Initial mild respiratory signs worsen over days to weeks as infection spreads through the flock. Secondary bacterial infections, when present, accelerate disease severity and extend clinical signs to air sac involvement. Mortality increases in complicated cases with systemic bacterial spread. Without secondary infection, chronic respiratory disease mortality remains relatively low, though production impacts are significant. The chronic carrier state develops in survivors, with periodic recurrence of clinical signs during stress periods.

Emergency symptoms requiring urgent intervention include sudden increases in mortality, severe respiratory distress with cyanosis, and rapid spread of clinical signs through previously unaffected flock sections. Marked depression with complete anorexia suggests systemic bacterial complications requiring immediate treatment. Facial swelling so severe that birds cannot open eyes or eat demands rapid response. Any mortality pattern significantly exceeding baseline levels warrants veterinary consultation and diagnostic investigation to differentiate chronic respiratory disease from more serious conditions.

Clinical examination forms the initial basis for chronic respiratory disease diagnosis in affected flocks. Veterinarians assess birds for characteristic respiratory signs including nasal discharge, facial swelling, and audible respiratory abnormalities. Physical examination reveals periorbital edema, conjunctivitis, and evidence of sinus involvement. Flock history including disease patterns, production impacts, and known mycoplasma status provides important context. Clinical findings guide selection of appropriate diagnostic testing to confirm mycoplasma involvement and identify secondary pathogens.

Diagnostic testing for chronic respiratory disease utilizes multiple methodologies to detect Mycoplasma gallisepticum infection. Serology using rapid plate agglutination, hemagglutination inhibition, or enzyme-linked immunosorbent assays detects antibody responses to mycoplasma exposure. Polymerase chain reaction testing provides direct detection of mycoplasma DNA from respiratory samples including tracheal or choanal swabs. Culture on specialized media allows organism isolation but requires extended incubation periods. Necropsy examination of affected birds reveals characteristic lesions including air sac thickening, exudate accumulation, and sinus inflammation. Secondary pathogen identification through culture and sensitivity testing guides antibiotic selection.

Differential diagnosis must consider other respiratory conditions producing similar clinical presentations. Infectious bronchitis causes acute respiratory signs that may precede or accompany mycoplasma infection. Newcastle disease produces respiratory involvement along with nervous system signs. Aspergillosis causes air sac lesions requiring differentiation from bacterial airsacculitis. Infectious laryngotracheitis produces severe respiratory distress potentially confused with complicated chronic respiratory disease. Accurate diagnosis is essential because treatment approaches differ significantly among these conditions.

Herd-level diagnostics characterize mycoplasma status across the operation and guide control program development. Serological monitoring of sample birds from each house establishes infection patterns. Routine surveillance testing enables early detection of new infections in previously negative flocks. Investigation of positive test results includes tracing potential introduction sources. Production record analysis correlating with test results quantifies disease impacts. Integration of laboratory findings with clinical and production data enables comprehensive understanding of chronic respiratory disease dynamics within the operation.

Emergency treatment for severe chronic respiratory disease cases focuses on rapid intervention to prevent mortality and limit progression. Birds in acute distress may require individual treatment with injectable antibiotics for immediate therapeutic effect. Isolation of severely affected individuals reduces transmission and allows focused care. Environmental optimization including improved ventilation and ammonia reduction supports respiratory function. Complicating bacterial infections require aggressive treatment to prevent systemic spread and death.

Medical management of chronic respiratory disease relies on antibiotic therapy targeting mycoplasma and secondary bacterial pathogens. Effective antibiotics include tetracyclines, fluoroquinolones, macrolides, and pleuromutilins, with specific selection based on veterinary guidance and local resistance patterns. Water medication allows flock-wide treatment with relatively rapid effect. Feed medication provides sustained antibiotic levels for extended treatment courses. Injectable antibiotics are reserved for individual valuable birds or severely affected cases. Withdrawal time compliance is essential for food-producing poultry, with accurate records documenting treatment dates and products.

Surgical intervention has no role in chronic respiratory disease management. The diffuse respiratory involvement and infectious nature of the condition preclude surgical approaches. Infraorbital sinus involvement sometimes prompts consideration of sinus drainage, but this procedure is impractical in commercial poultry and provides minimal benefit. Resources are better directed toward medical therapy and management improvements.

Supportive care enhances treatment outcomes and improves bird comfort during disease recovery. Environmental management reducing ammonia levels, dust, and temperature stress supports respiratory healing. Ensuring readily accessible feed and water maintains intake during illness. Vitamin supplementation, particularly vitamins A and E, supports respiratory tissue repair and immune function. Reduced stocking density temporarily decreases transmission pressure and environmental contamination.

Herd treatment protocols recognize that chronic respiratory disease affects flocks as populations rather than just individual birds. Strategic medication timing aligned with known stress periods prevents clinical recurrence in positive flocks. Treatment of the entire flock rather than just clinically affected birds addresses subclinical carriers. Extended treatment durations, typically five to seven days, ensure adequate tissue levels. Follow-up monitoring identifies treatment failures requiring protocol adjustment. Long-term management planning addresses the reality of persistent flock-level infection.

Treatment decision factors in chronic respiratory disease balance welfare, production, and economic considerations. Treatment costs including medication and labor must be weighed against expected production recovery. Withdrawal time implications for marketed birds influence treatment timing. Repeated treatment needs in positive flocks affect long-term economic viability. For breeder flocks, the consequences of vertical transmission to offspring influence decisions about flock retention versus early disposal. Veterinary consultation helps navigate these complex decisions while maintaining focus on animal welfare alongside production goals.

Recovery timeline following chronic respiratory disease treatment extends over one to three weeks for resolution of acute clinical signs. Initial improvement in respiratory sounds and behavior occurs within days of starting effective antibiotic therapy. Feed and water consumption return toward normal as birds feel better. Egg production in laying flocks may require two to three weeks or longer to return to previous levels. Complete restoration of previous production peaks may not occur, with persistent minor impacts reflecting residual respiratory damage.

Post-treatment care and monitoring ensure recovery progresses appropriately and identifies birds requiring additional intervention. Continued observation for respiratory signs detects treatment failures or disease recurrence. Production monitoring tracks return toward normal parameters. Mortality surveillance identifies birds that fail to recover despite treatment. Environmental management maintaining good air quality supports continued healing of respiratory tissues. Stress minimization during the recovery period reduces likelihood of clinical recurrence.

Prognosis factors in chronic respiratory disease recovery encompass treatment timing, complication severity, and management quality. Birds treated early before secondary bacterial complications develop generally recover well with minimal residual effects. Those with advanced airsacculitis and systemic involvement face guarded prognosis even with appropriate treatment. Ongoing management quality including ventilation, stocking density, and stress control strongly influences long-term outcomes. The carrier state persisting after clinical recovery means that prognosis relates to managing chronic infection rather than achieving cure.

Return to production considerations acknowledge the persistent nature of mycoplasma infection in recovered flocks. Broilers recovering from chronic respiratory disease may fail to achieve target weights and face increased processing condemnation. Layer flocks typically resume production but may not reach previous peak levels. Breeding flocks pose particular challenges because recovered birds continue shedding organisms that transmit vertically to offspring. Decisions regarding continued production from positive flocks versus replacement with mycoplasma-free stock involve complex economic and biosecurity calculations.

Vaccination protocols for chronic respiratory disease provide tools for managing infection in positive or at-risk flocks. Live vaccines using mild Mycoplasma gallisepticum strains establish controlled infection that stimulates immunity. Inactivated bacterin vaccines administered by injection provide protection without establishing infection. Vaccination programs typically target pullets before production onset in layer and breeder operations. Vaccine strain selection and timing require veterinary guidance based on specific operation circumstances. Vaccination cannot replace biosecurity but provides additional protection when exposure risk is significant.

Biosecurity measures form the foundation of chronic respiratory disease prevention in commercial poultry operations. Sourcing birds only from verified mycoplasma-free breeders eliminates vertical transmission introduction. Strict isolation of replacement birds until testing confirms negative status prevents horizontal introduction. Personnel and equipment movement controls between facilities prevent mechanical transmission. Distance from known positive operations reduces aerosol transmission risk. All-in-all-out production with thorough cleaning between flocks breaks transmission cycles.

Nutritional prevention strategies support respiratory health and immune function in poultry flocks. Adequate vitamin A maintains respiratory epithelium integrity and resistance to colonization. Antioxidant vitamins support immune cell function. Balanced nutrition meeting all nutrient requirements maintains overall health and disease resistance. Feed quality management preventing contamination with respiratory irritants protects tissue integrity.

Management practices supporting chronic respiratory disease prevention address both exposure and resistance factors. Excellent ventilation maintaining low ammonia levels protects respiratory tissues from damage. Appropriate stocking density reduces transmission opportunities and stress. Dust control through proper litter moisture management decreases respiratory irritation. Temperature management preventing cold stress maintains immune competence. Single-age operations eliminate ongoing transmission from older carrier birds to susceptible replacements.

Quarantine and testing protocols protect mycoplasma-free operations from disease introduction. All replacement birds must originate from verified negative sources with appropriate testing documentation. Quarantine periods with testing before flock integration detect infected birds before exposure occurs. Routine serological monitoring of established flocks provides early detection of any status changes. Rapid response to positive test results including investigation and corrective action prevents spread from new introductions. The investment in maintaining mycoplasma-free status is far smaller than the ongoing costs of managing positive flock operations.

Daily management and monitoring for chronic respiratory disease requires consistent attention to flock respiratory health. Regular observation periods during quiet times allow detection of subtle respiratory sounds indicating disease activity. Feed and water consumption monitoring reveals early changes suggesting illness. Production record review identifies declining egg numbers or growth rates that may signal disease recurrence. Mortality patterns including both rates and causes of death inform health status assessment. Staff training ensures all personnel can recognize respiratory disease signs and report appropriately.

Housing and environmental management directly influences chronic respiratory disease severity and clinical expression. Ventilation systems must maintain air quality with ammonia levels below ten parts per million to protect respiratory tissues. Humidity management prevents excessive moisture that promotes organism survival and respiratory irritation. Temperature control appropriate for bird age minimizes cold stress that triggers clinical recurrence. Dust reduction through appropriate litter moisture decreases respiratory challenge. Regular equipment maintenance ensures environmental control systems function as designed.

Herd health programs for mycoplasma-positive operations integrate ongoing management with strategic intervention. Veterinary consultation establishes monitoring protocols and treatment thresholds for the specific operation. Serological monitoring tracks antibody levels indicating disease activity. Strategic medication timing during known stress periods prevents clinical breaks. Production parameter tracking with established baselines enables early intervention when deviations occur. Documentation of all interventions and outcomes guides program refinement.

Record keeping and monitoring systems support effective chronic respiratory disease management. Flock health records document vaccination, testing, and treatment history. Production records including daily egg numbers, feed consumption, and mortality provide early warning of problems. Environmental monitoring logs track ventilation and temperature parameters. Treatment records maintain food safety compliance and antibiotic stewardship documentation. Trend analysis across multiple flocks and production cycles identifies patterns guiding management improvements.

Economic considerations in chronic respiratory disease management significantly influence program design. Ongoing medication costs in positive flocks represent substantial production expense. Production losses from reduced growth and egg output diminish returns. Processing condemnations from respiratory lesions impact broiler operation profitability. Vaccination program costs must be balanced against protection benefits. For many operations, investment in obtaining and maintaining mycoplasma-free status provides better long-term economic returns than continued management of positive flock infection.

High-risk breeds and production types for chronic respiratory disease include fast-growing commercial broilers facing elevated stress from rapid growth demands. Commercial layer breeds, particularly white egg-producing Leghorn types, show significant production impacts from mycoplasma infection. High-producing turkey varieties demonstrate substantial economic losses when affected by chronic respiratory disease. Game birds including pheasants and partridge show susceptibility when exposed, creating risks for operations near commercial poultry. All commercial poultry breeds face clinically significant disease when exposed to Mycoplasma gallisepticum.

Production type considerations influence chronic respiratory disease impact and management approaches. Layer operations face ongoing production losses throughout extended laying cycles, making prevention particularly valuable. Broiler operations experience condensed impact periods but significant cumulative losses across multiple flocks placed through contaminated facilities. Breeder operations must prevent infection or face vertical transmission consequences affecting customer flocks. Free-range and organic operations may face different exposure patterns depending on proximity to backyard or wild reservoir populations.

Genetic selection and testing for chronic respiratory disease resistance has been incorporated into primary breeder selection programs. Some commercial lines demonstrate relative resistance to mycoplasma colonization and clinical disease. Testing programs including serology and PCR identify infected individuals within breeding populations. Mycoplasma-free breeding programs through testing and elimination produce negative progeny for commercial operations. The poultry industry's establishment of mycoplasma-free breeder flocks represents a major achievement enabling disease control at commercial production levels when biosecurity is maintained.

Commonly co-occurring conditions with chronic respiratory disease include Mycoplasma synoviae infection, which frequently accompanies Mycoplasma gallisepticum in poultry populations. Colibacillosis caused by Escherichia coli represents the most important complicating secondary infection, transforming relatively mild mycoplasma infection into severe complicated disease. Infectious bronchitis virus predisposes to mycoplasma clinical expression and increases disease severity. Other respiratory viruses including Newcastle disease similarly interact synergistically with mycoplasma infection. Understanding these relationships guides diagnostic approaches and treatment protocols.

Conditions with similar symptoms requiring differentiation from chronic respiratory disease include several important poultry respiratory conditions. Infectious coryza caused by Avibacterium paragallinarum produces facial swelling and nasal discharge resembling mycoplasma infection but with more rapid onset and distinct odor. Fowl cholera can cause respiratory involvement among its multisystem effects. Aspergillosis produces chronic respiratory signs requiring differentiation from bacterial respiratory disease. Ornithobacterium rhinotracheale infection causes respiratory disease with some clinical overlap. Accurate diagnosis through appropriate laboratory testing ensures correct treatment selection.

Complications and sequelae of chronic respiratory disease extend impacts beyond primary respiratory involvement. Air sac disease developing from secondary E. coli invasion causes severe production losses and mortality. Chronic respiratory compromise persisting after clinical recovery reduces long-term performance. Vertical transmission from infected breeders perpetuates infection in offspring generations. Immunosuppression from chronic infection increases susceptibility to other diseases. The persistent carrier state ensures continued shedding and transmission risk throughout the lives of affected birds, creating ongoing challenges for disease management in positive operations.